Is Cellectar Biosciences, Inc. (CLRB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.2% / 30% | 199.0% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 4.2% / 33% | 199.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.9% / 33% | 91.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 4.2% / 33% | 199.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.9% / 33% | 91.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -170.3% | |
| Return on Assets (ROA) | -71.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$23M |
| Free Cash Flow | -$23M |
| Total Debt | $409,586 |
| Debt-to-Equity | 4.1 |
| Current Ratio | 3.0 |
| Total Assets | $15M |
Price & Trading
| Last Close | $2.90 |
| 50-Day MA | $3.21 |
| 200-Day MA | $4.37 |
| Avg Volume | 71K |
| Beta | 0.3 |
|
52-Week Range
$2.45
| |
About Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cellectar Biosciences, Inc. (CLRB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cellectar Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cellectar Biosciences, Inc.'s debt ratio?
Cellectar Biosciences, Inc.'s debt ratio is 4.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.9%.
What are Cellectar Biosciences, Inc.'s key financial metrics?
Cellectar Biosciences, Inc. has a market capitalization of $11M. Return on equity stands at -170.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.